Gary Patou

Director

Dr. Patou has served as a member of our Board since January 2004. Dr. Patou served as a Chief Medical Officer at Star Therapeutics Inc. since August 2020. Dr. Patou served as a member of the Board of Directors and Chief Medical Officer for BioIntervene Inc., a preclinical stage biopharmaceutical company, from January 2019 to September 2026. Previously, Dr. Patou, was an Executive Partner at MPM Capital from 2005 until 2020, and he has served as interim Chief Medical Officer in various MPM portfolio companies, including at Blade Therapeutics from October 2018 to December 2020. Prior to joining MPM, Dr. Patou was Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals Corp. from February 2004 to April 2005 following its merger with GeneSoft Pharmaceuticals, Inc. Prior to GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine and received his B.Sc. from University of London and his M.D. from University College London.

The power behind our progress

Driving innovation forward